Testing stool and bacteria clues for poor rectal cancer response
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at stool samples to see whether gut bacteria or other microbes help explain why some rectal cancers respond less well to treatment given before surgery. If you have mid or lower rectal cancer and are planning pre-surgery treatment, your information and stool sample may help researchers improve how treatment is chosen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed cancer of the lower or middle rectum (adenocarcinoma) and it is stage II or III.
- You are planning “neoadjuvant” treatment first (radiation with chemo and/or chemotherapy).
- You must be able to give informed consent and be 18 or older.
- You cannot take antibiotics during the month before your stool sample.
- You must not have a permanent or temporary stoma (ostomy), and you should not have had pelvic radiation in the past year.
- You should not be pregnant or breastfeeding; and you must use reliable birth control during treatment and for at least 8 weeks after the last course of radiochemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patterns in the gut microbiome (gut bacteria) and gut chemicals (metabolites) to predict how rectal cancer may do after planned surgery. By understanding these markers, researchers hope to better forecast prognosis and tailor follow-up.
This study is looking at immune cells (NK cells and ImmunoScore) in the blood of people with rectal cancer that hasn't spread. It may help doctors learn more about how the immune system responds to standard chemoradiation treatment.
This study uses MRI scans to try to predict whether your rectal cancer completely disappears after pre-surgery chemoradiotherapy. The goal is to better personalize treatment decisions, possibly helping some patients avoid surgery.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.